原力生命科学有限公司宣布任命叶祥胜博士为首席科学官

2020年7月29日，原力生命科学有限公司（IONOVA LIFE SCIENCE CO., LTD.，下简称为“原力”），一家扎根于粤港澳大湾区，以抗肿瘤药物研发为核心的创新型并已达到临床阶段的生物医药公司，近日宣布任命叶祥胜博士为公司首席科学官。加入原力之前，叶博士担任礼来中国/亚洲肿瘤研究部负责人，在制药行业拥有良好的药物发明成就。叶博士的加盟为原力带来了超过23年的药物发明和开发经验。

在礼来，叶博士领导了针对癌细胞周期和主要癌症信号通路的药物发明工作，贡献了8个临床候选药物，包括同类最佳的CDK4/6抑制剂abemaciclib，该药物获得了FDA授予的突破性药物称号，并于2017年9月被FDA优先批准。

叶博士还以其卓越的领导能力发起了基于基因组和表基因组的癌症药物发明研究工作。长期以来，作为负责药物研发转化的团队负责人，叶博士管理了从先导化合物优化到2期临床试验概念验证阶段的癌症研发组合，并交付了4个临床候选药物、2个IND（包括abemaciclib）和1个2期在研药物。

2011年初，叶博士被派驻上海，负责领导礼来中国/亚洲肿瘤发现计划。叶博士通过外部合作帮助中国团队为公司交付了2个临床候选药物。在中国，叶博士在多个行业联盟计划中担任领导角色，开发了关键的转化研究平台/技术能力，以支持礼来肿瘤学的全球研发战略。

原力董事长、美国国家工程院院士孙勇奎博士表示：“叶博士是一位经验丰富的癌症疾病生物学家，被公认为癌症药物发现领域的科学领导者，热衷于开发针对癌症治疗的新药。我们很高兴叶博士加入我们！叶博士带来了新药从发现到开发的丰富经验，这对于我们通过内部研发以及外部许可引进来扩展我们的研发管线非常有价值。作为一名成功的药物猎手，叶博士独特的技能、广泛的知识和卓越的成就对于扩展原力的新药研发管线以及推动公司的长期成功至关重要。”

有关原力的更多信息，请访问www.ionovabio.com。

Ionova Life Science Appoints Dr. Xiang Ye as Chief Scientific Officer

IONOVA LIFE SCIENCE CO., LTD., China, July 29, 2020 – IONOVA, a biotech company based at the Guangdong-Hong Kong-Macao Greater Bay Area, pioneering innovative approaches to developing novel medicines to treat cancer, today announced that Dr. Xiang Ye, former Head of Lilly Oncology Research China/Asia, has been named Chief Scientific Officer. Dr. Ye has a proven track record of drug hunting in the pharmaceutical industry, bringing to IONOVA more than 23 years of pharmaceutical discovery and development experiences.

At Lilly, Dr. Ye led the drug discovery efforts targeting cancer cell cycle and major cancer signaling pathways and contributed 8 clinical candidates, including abemaciclib, the best-in-class CDK4/6 inhibitor, which received breakthrough medicine designation and was approved in September 2017 by FDA through priority review. In his leadership capacity, Dr. Ye also initiated genomic and epigenomic-based cancer drug discovery research efforts. As enduring team leader responsible for transforming drug R&D, Dr. Ye managed a cancer R&D portfolio from lead optimization to proof of concept in phase 2 and delivered 4 clinical candidates, 2 INDs including abemaciclib, and 1 phase 2. In early 2011, Dr. Ye was relocated to Shanghai to build and lead Lilly Oncology Discovery program China/Asia. Dr. Ye helped deliver 2 clinical candidates from China through external collaboration. In China, Dr. Ye played leadership roles in several industry consortium programs and developed key translational research platform/technological capabilities to support Lilly Oncology global R&D strategy.

“Dr. Ye, a seasoned veteran of cancer disease biologist, is recognized as a scientific leader in cancer drug discovery research, and for his passion to develop novel medicines for cancer treatment.  We are thrilled to have him joining us,” said Dr. Yongkui Sun, Chairman of the Board, and a member of the US National Academy of Engineering. “Xiang brings extensive experiences driving compounds from discovery through development, which will be valuable as we expand our pipeline through internal R&D efforts as well as in-licensing opportunities. His unique skill set, broad-based knowledge, and track record of accomplishments as a successful drug hunter will be important in driving the expansion of IONOVA’s early-stage pipeline and in driving the company’s long-term success.”

For more information on IONOVA, visit www.ionovabio.com.

- END -

推荐阅读